Drugs / ZD03
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04693455 | Nov 2019 → Apr 2020 | — | Shanxi Zhendong Leading Biotechnology Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ZD03 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04693455 ↗ |
| Modality | Small molecule | “ZD03 is a novel small molecular drug.” NCT04693455 ↗ |
| Route | Oral | “proposed to be administered orally as capsules” NCT04693455 ↗ |